Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109054 | 1.00 | GRM5 (0.49) | GRM5NPC1RAB9ASCN9AAAK1 | |
| SCHEMBL4103721 | 0.91 | GRM5 (0.47) | GRM5NPC1RAB9ASCN9AAAK1 | |
| SCHEMBL4102259 | 0.86 | AAK1 (0.48) | GRM5SCN9AAAK1CTSSCTSK | |
| SCHEMBL2668326 | 0.83 | GRM5 (0.54) | GRM5NPC1RAB9ACXCR2HCAR3 | |
| SCHEMBL4114224 | 0.83 | GRM5 (0.50) | GRM5NPC1RAB9ACXCR2HCAR3 | |
| SCHEMBL12201476 | 0.81 | GRM5 (0.56) | GRM5NPC1RAB9ACXCR2HCAR3 | |
| SCHEMBL12201477 | 0.78 | GRM5 (0.52) | GRM5NPC1RAB9ACXCR2HCAR3 | |
| SCHEMBL4103735 | 0.78 | GRM5 (0.52) | GRM5NPC1RAB9ACXCR2HCAR3 | |
| SCHEMBL4114863 | 0.78 | GRM5 (0.42) | GRM5AAK1CTSSCTSK | |
| SCHEMBL4114293 | 0.78 | GRM5 (0.46) | GRM5NPC1RAB9ACXCR2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GRM5 2182/4885NPC1 2933/4885RAB9A 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.